spacer
home > pmps > spring 2007 > excipients brace for a market transformation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Excipients Brace for a Market Transformation

The global excipients market faces challenges that may also turn out to be significant opportunities, explains Hans Huttinga of Kerry Bioscience – Sheffield Pharma Ingredients

The pharmaceutical excipient market is undergoing a period of intense change, driven by structural alterations in the drug market and the evolution of global business. Many challenges lie ahead, but also many opportunities. There are certainly bullish projections for growth. Frost & Sullivan placed the total European excipients market at $1.13 billion in 2004, and expects to see growth to $1.39 billion by 2008. The world market in 2004 was estimated to be worth around $2.5 billion (1).

This rosy financial future will, however, come at a cost. Over the next few years, excipient manufacturers will have to rise to the challenge of simultaneously servicing two very different markets: one valuing partnership and innovation, the other seeking competitive prices coupled with consistency of supply.

THE BLOCKBUSTERS’ DEMISE

For many years, big pharma companies have relied on ‘blockbuster’ drugs employing patented novel molecules. These were developed to treat the greatest number of people suffering from the most common diseases, and their huge development costs were more than offset by the promise of high sales. At the 2006 Drug Discovery Conference, held in Boston, it was estimated that the cost of producing a successful new drug could now exceed $2 billion (2).

However, with effective patent lives of only around 10 years, increased pressure from HMOs to cut prescription costs, and ever more onerous regulation, blockbusters are increasingly under threat from low-cost generic medication. Cutting Edge Information has estimated that by 2008, over $80 billion worth of blockbusters’ patents will have expired, potentially wiping 80 per cent from established manufacturers’ market share (2). Drug companies are beginning to realise that they must adopt a new business model in which drugs are increasingly marketed to specialist treatment niches, positioned not as ‘me too’ but differentiator products, taking into account consumer preference factors such as appearance, ease of use and novel functionality.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hans Huttinga is the Strategic Marketing Director (Pharma Ingredients) of Kerry Bioscience – Sheffield Pharma Ingredients. Hans, who has worked for the Kerry Bioscience organisation since 2000, has accrued more than 15 years of experience in new business, commercialisation and development of highlyvalued pharmaceutical ingredients and life science products within the life science and pharma markets. He graduated as an Engineer in Biotechnology in 1989, and has a long track record in business creation, sales and marketing within profitable companies serving the excipient and cell nutrition markets, and supplying the pharmaceutical and biotechnology industries.
spacer
Hans Huttinga
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement